Preclinical evaluation of SCC244 (Glumetinib), a novel,...

  • Main
  • 2017 / 12
  • Preclinical evaluation of SCC244 (Glumetinib), a novel,...
Molecular Cancer Therapeutics 2017 / 12

Preclinical evaluation of SCC244 (Glumetinib), a novel, potent and highly selective inhibitor of c-Met in MET-dependent cancer models

Ai, Jing, Chen, Yi, Peng, Xia, Ji, Yinchun, Xi, Yong, Shen, Yanyan, Yang, Xinying, Su, Yi, Sun, Yi-Ming, Gao, Yinglei, Ma, Yuchi, Xiong, Bing, Shen, Jingkang, Ding, Jian, Geng, Meiyu
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Molecular Cancer Therapeutics
DOI:
10.1158/1535-7163.MCT-17-0368
Date:
December, 2017
File:
PDF, 13.72 MB
english, 2017
Conversion to is in progress
Conversion to is failed